Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17321018 | 0.88 | MAPT (0.55) | MAPTALDH1A1TSHRMAPK1ALOX15 | |
| SCHEMBL17321014 | 0.84 | PDE10A (0.43) | THRBMAPTALDH1A1MTNR1ACA2 | |
| SCHEMBL17324189 | 0.81 | MTNR1A (0.40) | THRBMAPTMTNR1ASMN1; SMN2TP53 | |
| SCHEMBL15898881 | 0.79 | MTNR1A (0.46) | MTNR1A | |
| SCHEMBL11582560 | 0.77 | ALDH1A1 (0.55) | THRBMAPTALDH1A1TSHRCA12 | |
| SCHEMBL17321028 | 0.77 | ALOX15 (0.41) | MAPTALDH1A1TSHRMTNR1AALOX15 | |
| SCHEMBL17321030 | 0.77 | ALOX15 (0.41) | MAPTALDH1A1TSHRMTNR1AALOX15 | |
| SCHEMBL15898860 | 0.73 | MTNR1A (0.33) | MTNR1AALOX15 | |
| SCHEMBL5643020 | 0.73 | TAAR1 (0.44) | ALDH1A1TSHRCA1CA2CA9 | |
| SCHEMBL17321038 | 0.72 | MAPT (0.56) | THRBMAPTPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | THRB 1314/4885MAPT 828/4885ALDH1A1 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.